• DECLARE-TIMI 58: Dapagliflozin reduces HF hospitalization in type 2 diabetes

    7 days ago - By Healio

    CHICAGO - The DECLARE-TIMI 58 trial of dapagliflozin in patients with type 2 diabetes who had or were at high risk for atherosclerotic CVD adds to the growing body of evidence demonstrating the favorable effects of SGLT2 inhibitors on CV risk.
    Results from the international, multicenter, double-blind, randomized, placebo-controlled trial, which were simultaneously published in The New England Journal of Medicine, linked dapagliflozin 10 mg , as compared with placebo, to a significant 17% relative risk reduction in the co-primary efficacy endpoint of a composite of
    Read more ...

     

  • REDUCE-IT: Icosapent ethyl reduces ischemic events in high-risk patients

    7 days ago - By Healio

    CHICAGO - In patients with elevated triglycerides at high CV risk despite statin therapy, icosapent ethyl was superior to placebo for reducing risk for ischemic events, according to results of the anticipated REDUCE-IT trial.
    The trial of icosapent ethyl , a pharmaceutical-grade omega-3 fatty acid, enrolled 8,179 patients who had fasting triglycerides 135 mg/dL to 499 mg/dL despite taking statins and who had established CVD or diabetes plus other risk factors. Patients were assigned icosapent ethyl 2 g twice
    Read more ...